VC
FTH

Vivo Capital’s Faeth Therapeutics FTH Stock Holding History

Vivo Capital’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.1M Hold
722,020
– – 1.65% 23
2026
Q1 		$22.8M Buy
+722,020
New +$14.4M 1.89% 19

Other funds holding FTH

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Vivo Capital's FTH Position: Q2 2026 in Review

Vivo Capital held its Faeth Therapeutics (FTH) position steady in Q2 2026 at 722,020 shares worth $18.1M. The position accounts for 1.65% of the portfolio, ranked #23.

Vivo Capital first reported a position in FTH in Q1 2026 and has held it in 2 quarters since. The position peaked at $22.8M in Q1 2026. 45 funds tracked by Wall St. Rank hold FTH as of Q2 2026.

  • Vivo Capital held 722,020 shares of Faeth Therapeutics worth $18.1M as of Q2 2026.
  • Vivo Capital left its Faeth Therapeutics share count unchanged in Q2 2026.
  • Faeth Therapeutics made up 1.65% of Vivo Capital's portfolio in Q2 2026, its #23 holding.
  • Vivo Capital first reported a position in Faeth Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vivo Capital's Faeth Therapeutics position peaked at $22.8M in Q1 2026.
  • 45 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q2 2026.

Based on Vivo Capital's 13F filing for Q2 2026, filed 14 Aug 2026.